Insider Analysis From Easton Associates: Are Patient Assistance Programs The Silver Bullet To Meet Affordability Challenges In China?
This article was originally published in PharmAsia News
Executive Summary
By Celia Deng, Zhiyi Tong and Paul Zhang
You may also be interested in...
Pfizer Pilot Aims Local To Help China Kick Smoking Habit
Innovative drug makers are resorting to patient assistance and commercial insurance programs for their high-priced therapies in China. Pfizer is test-driving a new approach for its smoking cessation drug.
China Approves Local Generics Of Glivec; Novartis Says Quality Doesn’t Come Close
Novartis plans to draw on the safety profile of Glivec and a patient assistance program to ward off new competitors in China.
China Approves Local Generics Of Glivec; Novartis Says Quality Doesn’t Come Close
Novartis plans to draw on the safety profile of Glivec and a patient assistance program to ward off new competitors in China.